What is Aeovian Pharmaceuticals?
Headquartered in San Francisco, Aeovian Pharmaceuticals operates at the intersection of advanced molecular biology and drug discovery. Since its inception in 2012, the company has focused on developing novel therapeutics designed to address complex medical conditions by targeting the mTORC1 pathway. By leveraging deep scientific expertise, Aeovian aims to translate fundamental biological insights into clinical-stage assets, positioning itself as a high-value player in the competitive landscape of precision medicine and longevity research.
How much funding has Aeovian Pharmaceuticals raised?
Aeovian Pharmaceuticals has raised a total of $142M across 3 funding rounds:
Series A
$37M
Debt
$50M
Series B
$55M
Series A (2019): $37M with participation from Sofinnova Investments, Evotec SE, Apollo Health Ventures, and venBio Partners
Debt (2024): $50M led by Hevolution Foundation
Series B (2025): $55M supported by Sofinnova, Luma Group, Wilson Sonsini, and Foresite Capital
Key Investors in Aeovian Pharmaceuticals
Sofinnova
A clinical-stage biopharmaceutical venture capital firm managing approximately $2B in assets, specializing in guiding entrepreneurs through drug development and regulatory processes.
Foresite Capital
A multi-stage investment firm that utilizes a data science-driven approach to fund breakthrough opportunities at the intersection of technology and biotechnology.
venBio Partners
A life sciences investment firm managing nearly $1.1 billion in capital, focused on partnering with industry leaders to develop innovative medicines for unmet medical needs.
What's next for Aeovian Pharmaceuticals?
With the recent capital injection, Aeovian Pharmaceuticals is well-positioned to transition its lead candidates through rigorous clinical validation. The strategic backing from top-tier life sciences investors provides the necessary runway to scale operations and refine its drug development platform. Moving forward, the company is expected to prioritize regulatory milestones and potential partnership opportunities, leveraging its robust intellectual property portfolio to address significant unmet medical needs in the global healthcare market.
See full Aeovian Pharmaceuticals company page
